Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Committee ...

Jaipur: A study by doctors at the govt-run JK Lon Hospital has found that nearly 43% of children with thalassemia who undergo ...

The Human Genome Project, launched in 1990 and completed in 2003, also moved the needle. Scientists had successfully ...

Now, it’s worth noting Stock Advisor's total average return is 1,061% — a market-crushing outperformance compared to 192% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

Attempting to cash in on what's likely to be a relatively short-lived mania isn't a good idea for most investors most of the ...

Many born with the genetic disorder thalassaemia major die before the age of 10. Donated blood can help keep them alive.

Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year -- Second pivotal development ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the acceptance of an abstract for oral ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

LONDON, GREATER LONDON, UNITED KINGDOM, October 14, 2025 /EINPresswire.com/ -- What Is The Expected Cagr For The Rare Disease Genome Editing Market Through 2025? The market size of genome editing for ...

Patients with sickle cell disease and beta-thalassemia treated with exagamglogene autotemcel reported substantial and ...

Dizziness is common in older adults and has links to a higher risk of falls, disability, and an overall decline in health. It can have different causes, requiring a diagnosis to find the right ...